Halozyme Therapeutics

Quarterly Financials

Values in thousands2025-12-312025-09-302025-06-302025-03-31
Revenue
$451,767
$354,264
$325,719
$264,861
Gross Profit
349,621
299,022
279,360
216,458
EBITDA
281,076
284,625
229,834
168,802
EBIT
254,396
223,254
209,332
148,353
Net Income
-141,591
175,225
165,160
118,095
Net Change In Cash
451,767
354,264
325,719
264,861
Free Cash Flow
217,602
175,567
98,148
153,271
Cash
133,820
419,665
61,861
176,328
Basic Shares
117,672
122,331
124,158
126,644

Annual Financials

Values in thousands2025-12-312024-12-312023-12-312022-12-31
Revenue
$1,396,611
$1,015,324
$829,253
$660,116
Gross Profit
1,091,175
855,907
636,892
520,812
EBITDA
904,344
656,539
451,947
315,506
EBIT
816,293
575,227
367,091
265,865
Net Income
316,889
444,091
281,594
202,129
Net Change In Cash
1,396,611
1,015,324
829,253
660,116
Cost of Revenue
115,476
Free Cash Flow
644,588
468,368
373,277
235,300
Cash
133,820
115,850
118,370
234,195
Basic Shares
123,904
129,424
134,197
140,608

Earnings Calls

QuarterEPS
2026-03-31
$0
2025-12-31
-$0.24
2025-09-30
$1.72
2025-06-30
$1.54